DNAtrix
Manufacturing · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2450 Holcombe Blvd Ste 200, Houston, Tex...Phone Number
(832) 930-2401Website
www.dnatrix.comRevenue
$6.2 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About DNAtrix
DNAtrix is a privately held biotech company developing virus-driven immunotherapies to treat cancer. Its proprietary adenovirus platform is based on an engineered version of the common cold virus that is designed to selectively infect and kill cancer cells while leaving healthy cells unharmed. The company's lead product candidate is DNX-2401, which will enter into a global pivotal Phase 3 clinical study for patients with recurrent glioblastoma. DNX-2401 is also being evaluated in a Phase 1 study for diffuse intrinsic pontine glioma, for which it has received FDA Fast Track and Rare Pediatric Disease designations. A second product candidate, DNX-2440, is in Phase 1 clinical testing in patients with colorectal and other cancers with liver metastasis. The company's investors include Morningside Ventures and Mercury Fund.Explore more
DNAtrix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is DNAtrix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if DNAtrix has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when DNAtrix launches new products
Click to see if DNAtrix had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check out if DNAtrix is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at DNAtrix
Competitive Alert! Recent activity has been detected by your competitor Masked Content
DNAtrix, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on DNAtrix recently announced quarterly report
Funding: Get notified immidiatlly once DNAtrix has new funding data
Recommended Actions
Find VP level buyers at DNAtrix
Find 2 more new buyers
Compare Similar Companies to DNAtrix
Compare insights from companies similar to DNAtrix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
DNAtrix is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
DNAtrix is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about DNAtrix.
DNAtrix financials insights
Gather financial insights about DNAtrix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2008
Other Financing Round
$479K
2010
Other Financing Round
$170K
2012
Other Financing Round
$4.5M
Private Equity
$885K
2013
Multiple Rounds
$2.5M
2014
Grant
$10.8M
Series B
$20M
2016
Grant
$2M
2020
Debt
$350K
DNAtrix Tech Stack
A closer look at the technologies used by DNAtrix
Most Recent Scoops
Funding
DNAtrix has received an SBA PPP loan for $350,000-1 million from Silicon Valley Bank, supporting the retention of 20 jobs.
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company
DNAtrix News & Media
DNAtrix Announces Oral Presentation of Positive Overall Survival Data with DNX-2401 in DIPG at the Society for Neuro-oncology (SNO) Annual Meeting
SAN DIEGO, Nov. 22, 2021 /PRNewswire/ -- DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, today announced that data from the Phase 1 study of DNX-2401 in diffuse intrinsic pontine glioma (DIPG) was presented in an oral presentation at the 26th Annual Meeting...DNAtrix Announces the Appointment of David Liebowitz, M.D., Ph.D., as Chief Medical Officer
HOUSTON, Sept. 14, 2021 /PRNewswire/ -- DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, today announced the appointment of David Liebowitz, M.D., Ph.D., an industry veteran with over 20 years of experience in oncology drug and viral vaccine development, as...DNAtrix to Present at the Raymond James Human Health Innovations Conference
HOUSTON, June 9, 2021 /PRNewswire/ -- DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, today announced that the company will present at the Raymond James Human Health Innovations Conference on Monday, June 21, 2021, at 1:20 pm ET. A live webcast of the...DNAtrix Announces First Patient Dosed in Clinical Study of DNX-2440, an OX40 Ligand Expressing Immunotherapy, in Colorectal Cancer and Other Cancers with Liver Metastasis
HOUSTON, March 4, 2021 /PRNewswire/ -- DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, today announced the treatment of the first patient in a Phase 1 dose-escalation and dose-expansion study of DNX-2440, an OX40 ligand encoding oncolytic adenovirus, in...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding DNAtrix
Sign Up For FreeTo access detailed company insights
DNAtrix is a privately held biotech company developing virus-driven immunotherapies to treat cancer. Its proprietary adenovirus platform is based on an engineered version of the common cold virus that is designed to selectively infect and kill cancer cells while leaving healthy cells unharmed. The company's lead product candidate is DNX-2401, which... Read More
